study_id: "CX-NSCLC-101"
protocol: "CX-101"
phase: "Phase I"

# Link to parent portfolio registry
portfolio_registry: "../../portfolio_registry.yml"

# Study-specific paths (relative to study root)
paths:
  raw_data: "data/raw"
  sdtm: "data/sdtm"
  adam: "data/adam"
  outputs: "outputs"
  logs: "logs"

# CDISC specifications (legacy)
cdisc:
  sdtm_version: "1.5"
  adam_version: "1.0"
  controlled_terminology: "2021-06-25"
  
  # Study-specific SDTM domains
  sdtm_domains:
    - DM
    - AE
    - CM
    - LB
    - VS
    - EX
  
  # Study-specific ADaM datasets
  adam_datasets:
    - ADSL
    - ADAE
    - ADLB
    - ADVS

# Analysis populations
populations:
  SAFETY: "Safety (received â‰¥1 dose)"

# Treatment arms
treatments:
  - arm_code: "A"
    arm_name: "Compound-X Dose Escalation"

# Study-specific validation rules
validation:
  critical_datasets: ["ADSL", "ADAE"]
  qc_method: "vendor_qc"  # CRO-delivered with sponsor oversight
  
  non_critical_datasets: ["ADLB", "ADVS"]
  qc_method_nc: "spot_check"
